Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于公司清算孙公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the liquidation of its subsidiary, Yizheng Huakang Medical Equipment Co., Ltd. It details the board meeting approval, the reasons for liquidation, and the impact on the company. The document does not contain financial statements or detailed financial analysis but is a formal disclosure of a corporate action related to subsidiary liquidation. It is not an annual or interim report, audit report, or earnings release. It is also not a regulatory certification or voting result. The content fits best under a general regulatory announcement category about corporate actions that do not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short (1452 characters), and it is a formal announcement rather than a report itself, so it is not a report publication announcement (RPA).
2022-03-28 Chinese
金陵药业关于拟续聘2022年度会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the proposed reappointment of the accounting firm Tianheng CPA Firm for the 2022 fiscal year. It details the firm's background, personnel, audit fees, and the approval process by the board and audit committee. The document does not contain any financial statements or audit reports themselves, but rather is a notice about the intention to reappoint the auditor, pending shareholder approval. The document length is under 5,000 characters and it is clearly an announcement about an audit-related matter, not the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about auditor appointment rather than the audit report or annual report itself.
2022-03-28 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2021 Annual Report" and contains detailed descriptions of the independent director's duties, attendance at board meetings, opinions on board resolutions, and committee activities throughout the year 2021. It references compliance with company law and regulations related to independent directors and shareholder rights protection. The content is a detailed narrative report on the independent director's work and oversight activities during the year, which is a form of management or board-related reporting. It is not a financial report like an annual report (10-K) or interim report (IR), nor is it a simple announcement or certification. It is not a proxy statement or voting result. The document focuses on the independent director's report on their duties and opinions, which fits best under Board/Management Information (MANG). The length (over 6,000 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2022-03-28 Chinese
金陵药业股份有限公司职业经理人绩效考核管理办法（试行）
Governance Information Classification · 95% confidence The document is a detailed internal management policy titled '职业经理人绩效考核管理办法 (试行)' which translates to 'Performance Assessment Management Measures for Professional Managers (Trial)'. It outlines principles, assessment criteria, procedures, and application of performance evaluations for senior management personnel within the company. There is no indication that this is a financial report, audit, earnings release, or any regulatory filing. Instead, it is a governance-related document detailing internal rules and management practices concerning performance assessment and incentives for executives. Therefore, the document best fits the category of Governance Information (CGR). The document length (6897 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2022-03-28 Chinese
2021年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report for the 2021 financial statements of Jinling Pharmaceutical Co., Ltd. It contains detailed auditor opinions, audit basis, key audit matters such as goodwill impairment and accounts receivable bad debt provisions, responsibilities of management and auditors, and extensive notes on accounting policies and financial statement preparation. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial statement notes indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and audit findings, not just an announcement or certification. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2021
2022-03-28 Chinese
2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2021 annual report summary of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the year 2021, including main accounting data, quarterly financial data, business overview, industry analysis, shareholder information, and important matters related to the company. The presence of comprehensive financial statements, business descriptions, and management discussion indicates this is a full annual report rather than a brief announcement or a regulatory filing. The document length is over 14,000 characters, supporting that it is a substantive report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.